Drug Profile
Ramucirumab - Eli Lilly and Company
Alternative Names: Anti-flk-1 monoclonal antibody - ImClone; Anti-KDR monoclonal antibody - ImClone; Anti-VEGFR 2 monoclonal antibody - ImClone; Cyramza; IMC-1121; IMC-1121-B; IMC-1C11 - ImClone; LY-3009806; Ramcilumab; ramsilmab; Ramsilomab; Ramsylmab; Ramsylumab; Sairamza; SilamzaLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Dyax
- Developer AstraZeneca; Basilea Pharmaceutica; Dana-Farber Cancer Institute; Eli Lilly; Eli Lilly and Company; Merck Sharp & Dohme; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Colorectal cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer
- Phase III Oesophageal cancer; Urogenital cancer
- Phase II Biliary cancer; Carcinoid tumour; Solid tumours; Synovial sarcoma
- Phase I/II Head and neck cancer; Pancreatic cancer; Soft tissue sarcoma
- No development reported Adenocarcinoma; Breast cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Renal cell carcinoma
Most Recent Events
- 02 Jun 2023 Efficacy and adverse events data from a phase II trial in non-small cell lung cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 23 Apr 2023 Eli Lilly and Company completes the phase Ib/II RACING study in Pancreatic cancer (First-line therapy, Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable) in Greece (IV) (NCT03745430)
- 19 Apr 2023 Eli Lilly and Company terminates a phase I/II trial in Synovial Sarcoma in US, Australia, Belgium, France, Germany, Japan, Italy, the Netherlands, Spain and the UK due to meeting protocol specified futility criteria (NCT04145700)